Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
HARS2 Monoclonal Antibody (OTI2D6), TrueMAB™, OriGene

Mouse Monoclonal Antibody
Supplier: OriGene TA503794S


Description
HARS2 Monoclonal antibody specifically detects HARS2 in Human samples. It is validated for Flow Cytometry, Immunohistochemistry (Paraffin), Western BlotSpecifications
HARS2 | |
Monoclonal | |
0.36 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
P06858 | |
Mouse | |
Affinity chromatography | |
RUO | |
4023 | |
-20° C, Avoid Freeze/Thaw Cycles | |
IgG1 |
Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot | |
OTI2D6 | |
Unconjugated | |
LPL | |
4631412B19Rik; D-tyrosyl-tRNA deacylase 1 homolog; EC 6.1.1.21; EGK_16929; HARS2; Hars2l; HARSL; HARSR; HARS-related; HisRS; histidine translase; histidine tRNA ligase 2, mitochondrial (putative); histidine-tRNA ligase homolog; Histidine--tRNA ligase-like; Histidyl-tRNA synthetase; histidyl-tRNA synthetase 2; histidyl-tRNA synthetase 2, mitochondrial; histidyl-tRNA synthetase 2, mitochondrial (putative); histidyl-tRNA synthetase 2, mitochondrial, hisRS; histidyl-tRNA synthetase-like; HO3; PRLTS2; Probable histidine--tRNA ligase, mitochondrial; probable histidyl-tRNA synthetase, mitochondrial; probable histidyl-tRNA synthetase, mitochondrial-like; putative histidyl-tRNA synthetase, mitochondrial; RGD1308426; zinc finger, matrin type 2; Zmat2 | |
Human recombinant protein fragment corresponding to amino acids 28-475 of human LPL produced in HEK293T. | |
30 μL | |
Primary | |
Human | |
Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction